Bio-Rad: With Low Debt And A Stock Price Drop, Is The Company Undervalued?
2025-05-09 12:32:01 ET
Summary
- Bio-Rad has a solid debt position with a 20.50% debt-to-equity ratio and a 5.99 current ratio.
- The first DCF model implemented in this article suggests that Bio-Rad is undervalued by 33.91%, while the second model indicates an undervaluation of only 0.53%.
- For 2025, the company projected a 0.25% revenue growth rate, which is, in my opinion, the main aspect of concern.
Investment Thesis
I rate Bio-Rad ( BIO ) with a buy rating. I start by mentioning that the low growth perspective is the negative aspect. For 2025, the company expects a 0.25% growth rate for its revenues, which might not sound promising for some investors. However, since I published my previous article on Bio-Rad in November 2024, the company's share price has declined by 30.81%. Due to this drop, the two discounted cash flow models implemented in this article suggest that Bio-Rad's share price will increase. The first discounted cash flow (DCF) model points out an undervaluation of 33.91%, while the second valuation indicates a 0.53% undervaluation....
Read the full article on Seeking Alpha
For further details see:
Bio-Rad: With Low Debt And A Stock Price Drop, Is The Company Undervalued?
NASDAQ: BIO
BIO Trading
11.5% G/L:
$277.42 Last:
471,754 Volume:
$274.72 Open:
